CN Patent

CN106924259A — 治疗方案

Assigned to S1 Pharmaceuticals Inc · Expires 2017-07-07 · 9y expired

What this patent protects

本发明进一步涉及用于治疗受试者中的所有人类性功能障碍包括机能减退的性欲障碍(HSDD)的化合物、药物组合物和方法。

USPTO Abstract

本发明进一步涉及用于治疗受试者中的所有人类性功能障碍包括机能减退的性欲障碍(HSDD)的化合物、药物组合物和方法。

Drugs covered by this patent

Addyi (FLIBANSERIN) · Sprout Pharms

Patent Metadata

Patent number: CN106924259A
Jurisdiction: CN
Classification: —
Expires: 2017-07-07
Drug substance claim: No
Drug product claim: No
Assignee: S1 Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.